Compare CVS Health Corp (CVS) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs L3Harris Technologies Inc — how do they compare? CVS Health Corp trades at $107.04 (market cap $135.48B), while L3Harris Technologies Inc trades at $289.94 (market cap $54.03B). The key difference: CVS Health Corp is far larger — about 2.5× L3Harris Technologies Inc's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | LHX | |
|---|---|---|
Market Cap | $135.48B | $54.03B |
Sector | Health | Industrials |
52-Week High | $106.18 | $378.48 |
52-Week Low | $58.75 | $261.17 |
Enterprise Value | $202.02B | $64.79B |
Dividend Yield | 2.51% | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
LHX trades at $288.69, down 0.72% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $2.72, beating estimates of $2.53, continuing a trend of earnings beats. Revenue grew to $21.87 billion in 2025, with net income margin improving to 7.34%. Recent contract wins include a U.S. Space Force satellite deal and U.S. Army communications orders, supporting growth prospects.
The outlook remains positive with a consensus price target of $367.50, implying 27% upside, and 75% of analysts rate it a Buy. Risks include execution on record $40.7 billion backlog, debt levels, and defense budget volatility. The stock offers dividend income with a $1.25 quarterly payout, balancing growth and income appeal for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
